Toxic oil syndromeT65.3

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 06.09.2023

Dieser Artikel auf Deutsch

Synonym(s)

TOS; Toxic oil syndrome

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

HistoryThis section has been translated automatically.

Tabuenca 1981

DefinitionThis section has been translated automatically.

Disease caused by poisoned edible oil with a phase-like course and great clinical similarity to chronic autoimmune diseases of the vascular connective tissue.

Occurrence/EpidemiologyThis section has been translated automatically.

Epidemic 1981 in Spain.

EtiopathogenesisThis section has been translated automatically.

Consumption of rapeseed oil denatured with aniline.

ManifestationThis section has been translated automatically.

Acute phase: Women and men are affected equally often.

Chronic phase: Women are affected 6 to 10 times more often than men.

Clinical featuresThis section has been translated automatically.

Acute phase: 7-10 days after consumption fever, dyspnea due to interstitial pneumonia and pulmonary edema, gastrointestinal complaints.

Subacute phase: After about 2 months, nonspecific pruriginous skin lesions, maculopapular or urticarial erythema, arthralgias, myalgias.

Chronic phase: From the 4th month, in 10-15% of patients neuromuscular syndrome with scleroderma-like or poikiloderma-like skin manifestations. Furthermore, livedo reticularis, Raynaud's syndrome, Sjögren's syndrome, carpal tunnel syndrome, dysphagia or pulmonary hypertension may occur.

LaboratoryThis section has been translated automatically.

eosinophilia (>1000 plates/mm3). IgE elevation. In 35-80% of cases ANA is positive.

Differential diagnosisThis section has been translated automatically.

Eosinophilic myalgia syndrome; pseudoscleroderma.

TherapyThis section has been translated automatically.

Symptomatic physical and external therapy (see also scleroderma, progressive systemic), causal therapy unknown. If only sclerotic skin changes are present (without systemic involvement), phototherapy with UVA1 (20 J/cm2, for 6-8 weeks, 4 times/week) or PUVA bath therapy.

In case of systemic involvement, proceed as in progressive systemic scleroderma.

Progression/forecastThis section has been translated automatically.

Chronic stage: Progression over years. In the acute stage death by pulmonary complications.

LiteratureThis section has been translated automatically.

  1. Bell S et al (1992) The toxic oil syndrome - an example of an exogenously induced autoimmune disease. dermatologist 43: 339-343
  2. Sanchez-Porro Valades P et al (2003) Toxic oil syndrome: survival in the whole cohort between 1981 and 1995 J Clin Epidemiol 56: 701-708
  3. Hubbard V et al (2003) Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol 148: 563-568

Authors

Last updated on: 06.09.2023

Author: Prof. Dr. med. Peter Altmeyer